Attributes | Values |
---|
rdf:type
| |
rdfs:seeAlso
| |
Description
| - Somatostatin receptor targeting is a valuable method to treat somatostatin receptor-positive tumours. In peptide receptor radionuclide therapy, it is essential to determine the highest activity that can be safely administered to the patient. As Y-90 emits no gamma rays, absorbed doses for Y-90 are usually estimated using the same peptide labelled with In-111. The aim of the study was to determine if replacement of Y-90/88 by In-111 affects the biodistribution profile of five selected somatostatin analogues in preclinical experiments. Materials and Methods: Radiolabelled peptides were atministered in to male Wistar rats. Results: The peptides under studs, labelled either with In-111 or with Y-88/90 showed similar distribution profiles in all tissues excepting the kidney. The kidney radioactivity uptake was significantly lower for Y-88/90-labeled peptide in comparison with the one of In-111. Conclusion: We conclude that a radiation-absorbed dose after Y-90-labelled somatostatin analogues appears to be lower than that predicted by the In-111-labelled peptide.
- Somatostatin receptor targeting is a valuable method to treat somatostatin receptor-positive tumours. In peptide receptor radionuclide therapy, it is essential to determine the highest activity that can be safely administered to the patient. As Y-90 emits no gamma rays, absorbed doses for Y-90 are usually estimated using the same peptide labelled with In-111. The aim of the study was to determine if replacement of Y-90/88 by In-111 affects the biodistribution profile of five selected somatostatin analogues in preclinical experiments. Materials and Methods: Radiolabelled peptides were atministered in to male Wistar rats. Results: The peptides under studs, labelled either with In-111 or with Y-88/90 showed similar distribution profiles in all tissues excepting the kidney. The kidney radioactivity uptake was significantly lower for Y-88/90-labeled peptide in comparison with the one of In-111. Conclusion: We conclude that a radiation-absorbed dose after Y-90-labelled somatostatin analogues appears to be lower than that predicted by the In-111-labelled peptide. (en)
|
Title
| - Different Radioactivity Uptake between Somatostatin Analogues Labelled with In-111 and Y-90/88 in Rat Kidney
- Different Radioactivity Uptake between Somatostatin Analogues Labelled with In-111 and Y-90/88 in Rat Kidney (en)
|
skos:prefLabel
| - Different Radioactivity Uptake between Somatostatin Analogues Labelled with In-111 and Y-90/88 in Rat Kidney
- Different Radioactivity Uptake between Somatostatin Analogues Labelled with In-111 and Y-90/88 in Rat Kidney (en)
|
skos:notation
| - RIV/00216208:11160/12:10124209!RIV13-MSM-11160___
|
http://linked.open...avai/riv/aktivita
| |
http://linked.open...avai/riv/aktivity
| - I, P(GAP304/10/1738), P(OC08006)
|
http://linked.open...iv/cisloPeriodika
| |
http://linked.open...vai/riv/dodaniDat
| |
http://linked.open...aciTvurceVysledku
| |
http://linked.open.../riv/druhVysledku
| |
http://linked.open...iv/duvernostUdaju
| |
http://linked.open...titaPredkladatele
| |
http://linked.open...dnocenehoVysledku
| |
http://linked.open...ai/riv/idVysledku
| - RIV/00216208:11160/12:10124209
|
http://linked.open...riv/jazykVysledku
| |
http://linked.open.../riv/klicovaSlova
| - kidney uptake; Y-90/88; In-111; somatostatin analogue (en)
|
http://linked.open.../riv/klicoveSlovo
| |
http://linked.open...odStatuVydavatele
| |
http://linked.open...ontrolniKodProRIV
| |
http://linked.open...i/riv/nazevZdroje
| |
http://linked.open...in/vavai/riv/obor
| |
http://linked.open...ichTvurcuVysledku
| |
http://linked.open...cetTvurcuVysledku
| |
http://linked.open...vavai/riv/projekt
| |
http://linked.open...UplatneniVysledku
| |
http://linked.open...v/svazekPeriodika
| |
http://linked.open...iv/tvurceVysledku
| - Lázníček, Milan
- Lázníčková, Alice
|
http://linked.open...ain/vavai/riv/wos
| |
issn
| |
number of pages
| |
http://localhost/t...ganizacniJednotka
| |